Despite the constant availability of new medications, improved vaccines and antibiotics, infectious diseases often spread rapidly claiming many deaths even in modern industrialised nations. There are several reasons for the persistence of infectious diseases. Many pathogens are highly adaptable, often develop multiple resistance to antibiotics or 'escape the clutches' of conventional medicines and vaccines. It is biotechnology's duty to keep up to date with these dynamic challenges.
The objective of ForBIMed is to discover new, pathogen- and host-specific biomarkers that can serve as a basis for new diagnostics, therapeutics and vaccinations. With these ForBIMed aims to allow for a faster and simpler distinction between bacterial and viral infections, as well as between resistance profiles within the different groups of pathogens. In addition, the characterisation of host specific immune parameters, based on which the risk of a transplant rejection or a virus reactivation while a patient is immune suppressed is assessed, represents one of the main focal points of this project.
Within ForBIMed, 11 university research groups and 9 companies collaborate under the leadership of Dr. Ralf Wagner, PhD, Asoc. Prof. at the University of Regensburg in eleven project groups.
The universities and companies participating in this research cluster are:
- Universität Regensburg
- Friedrich-Alexander-Universität-Erlangen-Nürnberg (FAU)
- Ludwig-Maximilians-Universität München (LMU)
- Technische Universität München (TU)
- Hyglos GmbH, Bernried
- NovaTec Immundiagnostica GmbH, Dietzenbach
- Mikrogen GmbH, Neuried
- Bruker Daltonik GmbH, Bremen
- Lophius Biosciences GmbH, Regensburg
- Juno Therapeutics GmbH, München
- 4SC Discovery GmbH, Planegg-Martinsried
- AmVac Research GmbH, Martinsried
- SIRION BIOTECH GmbH, Martinsried